

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 8407030439 DOC. DATE: 84/06/29 NOTARIZED: YES DOCKET #
 FACIL: 50-220 Nine Mile Point Nuclear Station, Unit 1, Niagara Power 05000220
 AUTH. NAME: AUTHORITY AFFILIATION
 GEMPGES, T. E. Niagara Mohawk Power Corp.
 RECIP. NAME: RECIPIENT AFFILIATION
 VASSALLO, D. B. Operating Reactors Branch 2

SUBJECT: Forwards response to Generic Ltr 84-11 re insps of BWR
 stainless steel piping, Submittal of previous results,
 associated w/IE Bulletins 82-03 & 82-02 inapplicable.

DISTRIBUTION CODE: A047S COPIES RECEIVED: LTR 1 ENCL 1 SIZE: 4
 TITLE: OR Submittal: Inservice Inspection/Testing

NOTES: 05000220
 OL: 08/22/69

RECIPIENT		COPIES		RECIPIENT		COPIES	
ID	CODE/NAME	LTTR	ENCL	ID	CODE/NAME	LTTR	ENCL
NRR	ORB2 BC 01	7	7				
INTERNAL:	ELD/HDS3	1	0	NRR/DE/MEB	15	1	1
	NRR/DE/MTEB	14	1	NRR/DL/TAPMG		1	1
	REG FILE	04	1	RGN1		1	1
EXTERNAL:	ACRS	16	10	LPDR	03	1	1
	NRC PDR	02	1	NSIC	05	1	1
	NTIS		1				

1. RECEIVED
 2. RECEIVED
 3. RECEIVED
 4. RECEIVED
 5. RECEIVED
 6. RECEIVED
 7. RECEIVED
 8. RECEIVED
 9. RECEIVED
 10. RECEIVED
 11. RECEIVED
 12. RECEIVED
 13. RECEIVED
 14. RECEIVED
 15. RECEIVED
 16. RECEIVED
 17. RECEIVED
 18. RECEIVED
 19. RECEIVED
 20. RECEIVED
 21. RECEIVED
 22. RECEIVED
 23. RECEIVED
 24. RECEIVED
 25. RECEIVED
 26. RECEIVED
 27. RECEIVED
 28. RECEIVED
 29. RECEIVED
 30. RECEIVED
 31. RECEIVED
 32. RECEIVED
 33. RECEIVED
 34. RECEIVED
 35. RECEIVED
 36. RECEIVED
 37. RECEIVED
 38. RECEIVED
 39. RECEIVED
 40. RECEIVED
 41. RECEIVED
 42. RECEIVED
 43. RECEIVED
 44. RECEIVED
 45. RECEIVED
 46. RECEIVED
 47. RECEIVED
 48. RECEIVED
 49. RECEIVED
 50. RECEIVED
 51. RECEIVED
 52. RECEIVED
 53. RECEIVED
 54. RECEIVED
 55. RECEIVED
 56. RECEIVED
 57. RECEIVED
 58. RECEIVED
 59. RECEIVED
 60. RECEIVED
 61. RECEIVED
 62. RECEIVED
 63. RECEIVED
 64. RECEIVED
 65. RECEIVED
 66. RECEIVED
 67. RECEIVED
 68. RECEIVED
 69. RECEIVED
 70. RECEIVED
 71. RECEIVED
 72. RECEIVED
 73. RECEIVED
 74. RECEIVED
 75. RECEIVED
 76. RECEIVED
 77. RECEIVED
 78. RECEIVED
 79. RECEIVED
 80. RECEIVED
 81. RECEIVED
 82. RECEIVED
 83. RECEIVED
 84. RECEIVED
 85. RECEIVED
 86. RECEIVED
 87. RECEIVED
 88. RECEIVED
 89. RECEIVED
 90. RECEIVED
 91. RECEIVED
 92. RECEIVED
 93. RECEIVED
 94. RECEIVED
 95. RECEIVED
 96. RECEIVED
 97. RECEIVED
 98. RECEIVED
 99. RECEIVED
 100. RECEIVED

to report on 11-03 and discuss of various observed : 11-03
 affixes and/or to illustrate, general facts and/or
 , 11-03 11-03 11-03 11-03 11-03 11-03 11-03 11-03 11-03 11-03

[illegible]

05500020

CLASS: 10

COMPTON		COMPTON		COMPTON		COMPTON	
TYPE	NO.	TYPE	NO.	TYPE	NO.	TYPE	NO.
TYPE 1	1	TYPE 1	1	TYPE 1	1	TYPE 1	1
TYPE 2	2	TYPE 2	2	TYPE 2	2	TYPE 2	2
TYPE 3	3	TYPE 3	3	TYPE 3	3	TYPE 3	3
TYPE 4	4	TYPE 4	4	TYPE 4	4	TYPE 4	4
TYPE 5	5	TYPE 5	5	TYPE 5	5	TYPE 5	5
TYPE 6	6	TYPE 6	6	TYPE 6	6	TYPE 6	6
TYPE 7	7	TYPE 7	7	TYPE 7	7	TYPE 7	7
TYPE 8	8	TYPE 8	8	TYPE 8	8	TYPE 8	8
TYPE 9	9	TYPE 9	9	TYPE 9	9	TYPE 9	9
TYPE 10	10	TYPE 10	10	TYPE 10	10	TYPE 10	10
TYPE 11	11	TYPE 11	11	TYPE 11	11	TYPE 11	11
TYPE 12	12	TYPE 12	12	TYPE 12	12	TYPE 12	12
TYPE 13	13	TYPE 13	13	TYPE 13	13	TYPE 13	13
TYPE 14	14	TYPE 14	14	TYPE 14	14	TYPE 14	14
TYPE 15	15	TYPE 15	15	TYPE 15	15	TYPE 15	15
TYPE 16	16	TYPE 16	16	TYPE 16	16	TYPE 16	16
TYPE 17	17	TYPE 17	17	TYPE 17	17	TYPE 17	17
TYPE 18	18	TYPE 18	18	TYPE 18	18	TYPE 18	18
TYPE 19	19	TYPE 19	19	TYPE 19	19	TYPE 19	19
TYPE 20	20	TYPE 20	20	TYPE 20	20	TYPE 20	20

June 29, 1984

Director of Nuclear Reactor Regulation
Attention: Mr. Domenic B. Vassallo, Chief
Operating Reactors Branch No. 2
Division of Licensing
U. S. Nuclear Regulatory Commission
Washington, D.C. 20555

Re: Nine Mile Point Unit 1
Docket No. 50-220
DPR-63

Dear Mr. Vassallo:


Attached is Niagara Mohawk's response to Generic Letter 84-11 dated April 19, 1984, regarding inspections of boiling water reactor stainless steel piping. In general, Niagara Mohawk's response follows the staff recommendations in Generic Letter 84-11. It should be noted Nine Mile Point Unit 1 was excluded from earlier Inspection and Enforcement Bulletins 82-03 and 83-02. Therefore, submittal of previous results associated with those bulletins are not applicable.

Very truly yours,

T. E. Lempges

T. E. Lempges
Vice President
Nuclear Generation

TEL/AJP:bd
Attachment



*Adm
11*

1. The first part of the report is a general introduction to the subject of the study. It discusses the importance of the study and the objectives of the research.

2. The second part of the report is a detailed description of the methodology used in the study. It includes information about the sample size, the data collection methods, and the statistical analysis techniques.

3. The third part of the report is a discussion of the results of the study. It presents the findings of the research and discusses their implications for the field of study.

4. The fourth part of the report is a conclusion and a summary of the main findings of the study.

5. The fifth part of the report is a list of references and a bibliography of the sources used in the study.

6. The sixth part of the report is a list of appendices and a bibliography of the sources used in the study.

UNITED STATES
NUCLEAR REGULATORY COMMISSION

In the Matter of)

NIAGARA MOHAWK POWER CORPORATION)
(Nine Mile Point Nuclear Station)
Unit No. 1))

Docket No. 50-220

AFFIRMATION

I, Thomas E. Lempges, Vice President, Nuclear Generation, a duly authorized officer of Niagara Mohawk Power Corporation, licensee in the captioned proceeding, certify that the information presented herein, indicates Niagara Mohawk's current plans for Nine Mile Point Unit 1 in response to Generic Letter 84-11.

NIAGARA MOHAWK POWER CORPORATION

By Thomas E. Lempges
Thomas E. Lempges
Vice President
Nuclear Generation

Subscribed and sworn to before
me on this 29th day of June, 1984

Christine Austin
NOTARY PUBLIC

CHRISTINE AUSTIN
Notary Public in the State of New York
Qualified in Onondaga Co. No. 4787687
My Commission Expires March 30, 1985

INTERNAL SECURITY
New York
1947
NY 65-15874
NY 65-15874

RESPONSE TO NUCLEAR REGULATORY COMMISSION

GENERIC LETTER 84-11 DATED APRIL 19, 1984

REGARDING INSPECTIONS OF BWR STAINLESS STEEL PIPING

In response to Generic Letter 84-11, Niagara Mohawk currently plans to do the following*:

1. Piping susceptible to intergranular stress corrosion cracking will be inspected (as indicated below in item 2) once each refueling cycle commencing with Niagara Mohawk's next scheduled refueling outage.
2. Stainless steel welds susceptible to intergranular stress corrosion cracking will be inspected in piping equal or greater than four inches in diameter, in systems operating over 200°F, that are part of or connected to the reactor coolant pressure boundary, out to the second isolation valve as follows.
 - a. Inspection of 20 percent of the welds in each pipe size of intergranular stress corrosion cracking sensitive welds not inspected previously (but no less than four welds) and reinspection of 20 percent of the welds in each pipe size inspected previously (but not less than two welds) and found not to be cracked. This sample will be selected primarily from weld locations shown by experience to have the highest propensity for cracking.
 - b. Unrepaired cracked welds.
 - c. Inspection of weld overlays on welds where circumferential cracks longer than ten percent of circumference will be measured. Disposition of any findings will be reviewed on a case-by-case basis.
 - d. Inspection of any weld treated by induction heating stress improvement which has not had post treatment ultrasonic test acceptance.
 - e. In the event new cracks or significant growth of old cracks are found, inspection scope shall be expanded in accordance with Inspection and Enforcement Bulletin 83-02.
3. Inspections shall be performed in accordance with the Nine Mile Point Unit 1 Technical Specifications. Inspections shall be performed by individuals qualified to A) the ASME Boiler and Pressure Vessel Code, Section XI and B) the (40-hr) Ultrasonic Testing Operator Training Course for intergranular stress corrosion cracking developed by the Electric Power Research Institute and the Nondestructive Examination Center, or an equivalent Nuclear Regulatory Commission approved course.

[illegible]

11

Figure 1: Schematic representation of the experimental design. The figure is divided into two main sections: (a) Pretest and (b) Main experiment. Section (a) shows a sequence of steps: 1. Pretest, 2. Pretest, 3. Pretest, 4. Pretest, 5. Pretest, 6. Pretest, 7. Pretest, 8. Pretest, 9. Pretest, 10. Pretest, 11. Pretest, 12. Pretest, 13. Pretest, 14. Pretest, 15. Pretest, 16. Pretest, 17. Pretest, 18. Pretest, 19. Pretest, 20. Pretest, 21. Pretest, 22. Pretest, 23. Pretest, 24. Pretest, 25. Pretest, 26. Pretest, 27. Pretest, 28. Pretest, 29. Pretest, 30. Pretest, 31. Pretest, 32. Pretest, 33. Pretest, 34. Pretest, 35. Pretest, 36. Pretest, 37. Pretest, 38. Pretest, 39. Pretest, 40. Pretest, 41. Pretest, 42. Pretest, 43. Pretest, 44. Pretest, 45. Pretest, 46. Pretest, 47. Pretest, 48. Pretest, 49. Pretest, 50. Pretest, 51. Pretest, 52. Pretest, 53. Pretest, 54. Pretest, 55. Pretest, 56. Pretest, 57. Pretest, 58. Pretest, 59. Pretest, 60. Pretest, 61. Pretest, 62. Pretest, 63. Pretest, 64. Pretest, 65. Pretest, 66. Pretest, 67. Pretest, 68. Pretest, 69. Pretest, 70. Pretest, 71. Pretest, 72. Pretest, 73. Pretest, 74. Pretest, 75. Pretest, 76. Pretest, 77. Pretest, 78. Pretest, 79. Pretest, 80. Pretest, 81. Pretest, 82. Pretest, 83. Pretest, 84. Pretest, 85. Pretest, 86. Pretest, 87. Pretest, 88. Pretest, 89. Pretest, 90. Pretest, 91. Pretest, 92. Pretest, 93. Pretest, 94. Pretest, 95. Pretest, 96. Pretest, 97. Pretest, 98. Pretest, 99. Pretest, 100. Pretest. Section (b) shows a sequence of steps: 1. Pretest, 2. Pretest, 3. Pretest, 4. Pretest, 5. Pretest, 6. Pretest, 7. Pretest, 8. Pretest, 9. Pretest, 10. Pretest, 11. Pretest, 12. Pretest, 13. Pretest, 14. Pretest, 15. Pretest, 16. Pretest, 17. Pretest, 18. Pretest, 19. Pretest, 20. Pretest, 21. Pretest, 22. Pretest, 23. Pretest, 24. Pretest, 25. Pretest, 26. Pretest, 27. Pretest, 28. Pretest, 29. Pretest, 30. Pretest, 31. Pretest, 32. Pretest, 33. Pretest, 34. Pretest, 35. Pretest, 36. Pretest, 37. Pretest, 38. Pretest, 39. Pretest, 40. Pretest, 41. Pretest, 42. Pretest, 43. Pretest, 44. Pretest, 45. Pretest, 46. Pretest, 47. Pretest, 48. Pretest, 49. Pretest, 50. Pretest, 51. Pretest, 52. Pretest, 53. Pretest, 54. Pretest, 55. Pretest, 56. Pretest, 57. Pretest, 58. Pretest, 59. Pretest, 60. Pretest, 61. Pretest, 62. Pretest, 63. Pretest, 64. Pretest, 65. Pretest, 66. Pretest, 67. Pretest, 68. Pretest, 69. Pretest, 70. Pretest, 71. Pretest, 72. Pretest, 73. Pretest, 74. Pretest, 75. Pretest, 76. Pretest, 77. Pretest, 78. Pretest, 79. Pretest, 80. Pretest, 81. Pretest, 82. Pretest, 83. Pretest, 84. Pretest, 85. Pretest, 86. Pretest, 87. Pretest, 88. Pretest, 89. Pretest, 90. Pretest, 91. Pretest, 92. Pretest, 93. Pretest, 94. Pretest, 95. Pretest, 96. Pretest, 97. Pretest, 98. Pretest, 99. Pretest, 100. Pretest. The figure also includes a legend for the Pretest and Main experiment sections.

Figure 1. The proposed model for the effect of the perceived effort on the perceived exertion.

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The number of transformed cells was determined by the number of colonies growing on the selective medium. The results are the mean of three independent experiments. Error bars represent the standard deviation.

[illegible][illegible][illegible]

1. 凡在本市行政区域内从事经营活动的个体工商户、企业法人、其他经济组织（以下统称“经营者”），均应当遵守本规定。

[illegible]

1. *Pharmaceuticals* (1997) 10, 11. *Pharmaceuticals* (1998) 11, 12. *Pharmaceuticals* (1999) 12, 13. *Pharmaceuticals* (2000) 13, 14. *Pharmaceuticals* (2001) 14, 15. *Pharmaceuticals* (2002) 15, 16. *Pharmaceuticals* (2003) 16, 17. *Pharmaceuticals* (2004) 17, 18. *Pharmaceuticals* (2005) 18, 19. *Pharmaceuticals* (2006) 19, 20. *Pharmaceuticals* (2007) 20, 21. *Pharmaceuticals* (2008) 21, 22. *Pharmaceuticals* (2009) 22, 23. *Pharmaceuticals* (2010) 23, 24. *Pharmaceuticals* (2011) 24, 25. *Pharmaceuticals* (2012) 25, 26. *Pharmaceuticals* (2013) 26, 27. *Pharmaceuticals* (2014) 27, 28. *Pharmaceuticals* (2015) 28, 29. *Pharmaceuticals* (2016) 29, 30. *Pharmaceuticals* (2017) 30, 31. *Pharmaceuticals* (2018) 31, 32. *Pharmaceuticals* (2019) 32, 33. *Pharmaceuticals* (2020) 33, 34. *Pharmaceuticals* (2021) 34, 35. *Pharmaceuticals* (2022) 35, 36. *Pharmaceuticals* (2023) 36, 37. *Pharmaceuticals* (2024) 37, 38. *Pharmaceuticals* (2025) 38, 39. *Pharmaceuticals* (2026) 39, 40. *Pharmaceuticals* (2027) 40, 41. *Pharmaceuticals* (2028) 41, 42. *Pharmaceuticals* (2029) 42, 43. *Pharmaceuticals* (2030) 43, 44. *Pharmaceuticals* (2031) 44, 45. *Pharmaceuticals* (2032) 45, 46. *Pharmaceuticals* (2033) 46, 47. *Pharmaceuticals* (2034) 47, 48. *Pharmaceuticals* (2035) 48, 49. *Pharmaceuticals* (2036) 49, 50. *Pharmaceuticals* (2037) 50, 51. *Pharmaceuticals* (2038) 51, 52. *Pharmaceuticals* (2039) 52, 53. *Pharmaceuticals* (2040) 53, 54. *Pharmaceuticals* (2041) 54, 55. *Pharmaceuticals* (2042) 55, 56. *Pharmaceuticals* (2043) 56, 57. *Pharmaceuticals* (2044) 57, 58. *Pharmaceuticals* (2045) 58, 59. *Pharmaceuticals* (2046) 59, 60. *Pharmaceuticals* (2047) 60, 61. *Pharmaceuticals* (2048) 61, 62. *Pharmaceuticals* (2049) 62, 63. *Pharmaceuticals* (2050) 63, 64. *Pharmaceuticals* (2051) 64, 65. *Pharmaceuticals* (2052) 65, 66. *Pharmaceuticals* (2053) 66, 67. *Pharmaceuticals* (2054) 67, 68. *Pharmaceuticals* (2055) 68, 69. *Pharmaceuticals* (2056) 69, 70. *Pharmaceuticals* (2057) 70, 71. *Pharmaceuticals* (2058) 71, 72. *Pharmaceuticals* (2059) 72, 73. *Pharmaceuticals* (2060) 73, 74. *Pharmaceuticals* (2061) 74, 75. *Pharmaceuticals* (2062) 75, 76. *Pharmaceuticals* (2063) 76, 77. *Pharmaceuticals* (2064) 77, 78. *Pharmaceuticals* (2065) 78, 79. *Pharmaceuticals* (2066) 79, 80. *Pharmaceuticals* (2067) 80, 81. *Pharmaceuticals* (2068) 81, 82. *Pharmaceuticals* (2069) 82, 83. *Pharmaceuticals* (2070) 83, 84. *Pharmaceuticals* (2071) 84, 85. *Pharmaceuticals* (2072) 85, 86. *Pharmaceuticals* (2073) 86, 87. *Pharmaceuticals* (2074) 87, 88. *Pharmaceuticals* (2075) 88, 89. *Pharmaceuticals* (2076) 89, 90. *Pharmaceuticals* (2077) 90, 91. *Pharmaceuticals* (2078) 91, 92. *Pharmaceuticals* (2079) 92, 93. *Pharmaceuticals* (2080) 93, 94. *Pharmaceuticals* (2081) 94, 95. *Pharmaceuticals* (2082) 95, 96. *Pharmaceuticals* (2083) 96, 97. *Pharmaceuticals* (2084) 97, 98. *Pharmaceuticals* (2085) 98, 99. *Pharmaceuticals* (2086) 99, 100. *Pharmaceuticals* (2087) 100, 101. *Pharmaceuticals* (2088) 101, 102. *Pharmaceuticals* (2089) 102, 103. *Pharmaceuticals* (2090) 103, 104. *Pharmaceuticals* (2091) 104, 105. *Pharmaceuticals* (2092) 105, 106. *Pharmaceuticals* (2093) 106, 107. *Pharmaceuticals* (2094) 107, 108. *Pharmaceuticals* (2095) 108, 109. *Pharmaceuticals* (2096) 109, 110. *Pharmaceuticals* (2097) 110, 111. *Pharmaceuticals* (2098) 111, 112. *Pharmaceuticals* (2099) 112, 113. *Pharmaceuticals* (2100) 113, 114. *Pharmaceuticals* (2101) 114, 115. *Pharmaceuticals* (2102) 115, 116. *Pharmaceuticals* (2103) 116, 117. *Pharmaceuticals* (2104) 117, 118. *Pharmaceuticals* (2105) 118, 119. *Pharmaceuticals* (2106) 119, 120. *Pharmaceuticals* (2107) 120, 121. *Pharmaceuticals* (2108) 121, 122. *Pharmaceuticals* (2109) 122, 123. *Pharmaceuticals* (2110) 123, 124. *Pharmaceuticals* (2111) 124, 125. *Pharmaceuticals* (2112) 125, 126. *Pharmaceuticals* (2113) 126, 127. *Pharmaceuticals* (2114) 127, 128. *Pharmaceuticals* (2115) 128, 129. *Pharmaceuticals* (2116) 129, 130. *Pharmaceuticals* (2117) 130, 131. *Pharmaceuticals* (2118) 131, 132. *Pharmaceuticals* (2119) 132, 133. *Pharmaceuticals* (2120) 133, 134. *Pharmaceuticals* (2121) 134, 135. *Pharmaceuticals* (2122) 135, 136. *Pharmaceuticals* (2123) 136, 137. *Pharmaceuticals* (2124) 137, 138. *Pharmaceuticals* (2125) 138, 139. *Pharmaceuticals* (2126) 139, 140. *Pharmaceuticals* (2127) 140, 141. *Pharmaceuticals* (2128) 141, 142. *Pharmaceuticals* (2129) 142, 143. *Pharmaceuticals* (2130) 143, 144. *Pharmaceuticals* (2131) 144, 145. *Pharmaceuticals* (2132) 145, 146. *Pharmaceuticals* (2133) 146, 147. *Pharmaceuticals* (2134) 147, 148. *Pharmaceuticals* (2135) 148, 149. *Pharmaceuticals* (2136) 149, 150. *Pharmaceuticals* (2137) 150, 151. *Pharmaceuticals* (2138) 151, 152. *Pharmaceuticals* (2139) 152, 153. *Pharmaceuticals* (2140) 153, 154. *Pharmaceuticals* (2141) 154, 155. *Pharmaceuticals* (2142) 155, 156. *Pharmaceuticals* (2143) 156, 157. *Pharmaceuticals* (2144) 157, 158. *Pharmaceuticals* (2145) 158, 159. *Pharmaceuticals* (2146) 159, 160. *Pharmaceuticals* (2147) 160, 161. *Pharmaceuticals* (2148) 161, 162. *Pharmaceuticals* (2149) 162, 163. *Pharmaceuticals* (2150) 163, 164. *Pharmaceuticals* (2151) 164, 165. *Pharmaceuticals* (2152) 165, 166. *Pharmaceuticals* (2153) 166, 167. *Pharmaceuticals* (2154) 167, 168. *Pharmaceuticals* (2155) 168, 169. *Pharmaceuticals* (2156) 169, 170. *Pharmaceuticals* (2157) 170, 171. *Pharmaceuticals* (2158) 171, 172. *Pharmaceuticals* (2159) 172, 173. *Pharmaceuticals* (2160) 173, 174. *Ph*

[illegible]

4. Leak detection and leakage limits will be addressed separately in a Technical Specifications amendment as requested by your letter of June 6, 1984.
5. Crack evaluation and repairs will meet the intent of Attachment 2 to Generic Letter 84-11.

* This program applies to service sensitive materials. However, material which has been demonstrated to be corrosion-resistant material as discussed in NUREG 0313 - Rev. 1 and which has been installed at Nine Mile Point Unit 1, will not be subject to this type of inspection program.

